Crohn's Disease

Higher cumulative exposure to systemic antibiotic therapy may be associated with higher risk for the development of inflammatory bowel disease, according to research published in Lancet Gastroenterology & Hepatology.

Dilating small intestinal Crohn’s disease strictures with balloon-assisted enteroscopy had good short-term technical and clinical efficacy, according to a meta-analysis published in Alimentary Pharmacology & Therapeutics.

Achieving endoscopic remission may be difficult for patients with Crohn’s disease with larger and deep ulcers in the ileum or rectum, according to results published in the American Journal of Gastroenterology.

Patients with inflammatory bowel disease discontinued methotrexate therapy at twice the rate seen in those who used optimized thiopurine therapy, according to study results.

After 52 weeks of treatment, Stelara helped induce clinical and endoscopic remission in patients with refractory Crohn’s disease, according to study results.

Colorectal cancer screening rates in recent years have significantly decreased in at-risk groups such patients aged 50 to 52 years and patients under 50 years with Crohn’s disease and ulcerative colitis, according to data collected by the Blue Cross Blue Shield Association and reported in The Health of America report, Rise in Chronic Conditions is Putting More Americans at risk for Colorectal Cancer.

Six months of combined impact and resistance training improved bone mineral density and muscle function in adults with Crohn’s disease, according to study results.

Fecal microbiota transplantation for recurrent Clostridioides difficile infection in patients with inflammatory bowel disease was safe and well tolerated and resulted in a high rate of C. difficile decolonization, according to a study published in Gastroenterology.

Individuals with atopic diseases such as asthma and atopic dermatitis appeared to be at higher risk for developing inflammatory bowel disease, according to study results.

The European Commission has extended approval for Celltrion Healthcare’s subcutaneous infliximab biosimilar to treat adults with ankylosing spondylitis, Crohn’s disease, ulcerative colitis, psoriatic arthritis and psoriasis.